US FDA approves Shilpa Medicare's Pemetrexed Injection

US FDA approves Shilpa Medicare's Pemetrexed Injection

Pemetrexed injection is used in the treatment of Non-small cell lung cancer & Malignant pleural mesothelioma as approved in the Prescribing Information.

FPJ Web DeskUpdated: Tuesday, May 23, 2023, 03:48 PM IST
article-image
US FDA approves Shilpa Medicare's Pemetrexed Injection | LinkedIn

Shilpa Medicare’s New Drug Application for Pemetrexed Injection 1000 mg/100 ml, 500 mg/50 ml & 100 mg/10 ml, Ready to Use formulation is approved by US FDA, the company announced through an exchange filing.

This is the first NDA product approval received by the Company under 505(b)(2) application, which is a unique formulation supplied as ready to use product solution. This product is required to be administered intravenously without any further dilution. The product is stable at room temperature.

The company has developed Pemetrexed formulation as liquid/ ready to use injection against Lyophilized powder formulation of reference ALIMTA. The product approval has been received for the application filed from a third party manufacturing site. The Company has already entered into a commercialization agreement with Amneal Pharmaceuticals LLC for the US Market.

Pemetrexed injection is used in the treatment of Non-small cell lung cancer & Malignant pleural mesothelioma as approved in the Prescribing Information.

According to IQVIA MAT Q1 2023 data, the US market for Pemetrexed Injection is approximately USD 735.3 Million.

(To receive our E-paper on WhatsApp daily, please click here.  To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

RECENT STORIES

Bengaluru-based virtual platform Airmeet lays off 30% of workforce: Report

Bengaluru-based virtual platform Airmeet lays off 30% of workforce: Report

Maruti Suzuki expects production loss in Q1; anticipates some relief in Q2

Maruti Suzuki expects production loss in Q1; anticipates some relief in Q2

Ahead of share market: Top events to impact trading next week

Ahead of share market: Top events to impact trading next week

JPMorgan Chase to layoff 500 employees: Report

JPMorgan Chase to layoff 500 employees: Report

Aurobindo Pharma to transfer shares in subsidiary to Curateq Biologics

Aurobindo Pharma to transfer shares in subsidiary to Curateq Biologics